Renin-angiotensin system modulators in COVID-19 patients with hypertension: friend or foe?

Conclusion: Current evidence reveals no increased risk of COVID-19 infection among hypertensive patients on ACEIs/ARBs compared to other antihypertensive medications. Several studies have demonstrated no detrimental effects of RAS modulators on clinical severity, hospital/intensive care unit stay, ventilation and mortality. Hence, we can conclude that neither ARBs nor ACEIs treatment will cause any side effects or undesirable interactions in COVID-19 infected hypertensive patients.PMID:34414841 | DOI:10.1080/10641963.2021.1963070

Source: Clinical and Experimental Hypertension - August 20, 2021 Category: Cardiology Authors: Shakhi Shylesh C M Arya V S Kanthlal S K Uma Devi P Source Type: research